Quote:

---

" the acquisition of a clinical-stage, orphan product candidate, of which the development is being funded by agencies within the United States government."

Any guesses at what this might be?
Diagnostic? Therapeutic?

---

Seems like the therapeutic division although they been talking about adding assets in diagnostic.

If therapeutic, here's an example of a company with an orphan product candidate that has good reason to do a deal. I am sure there are many other companies like it.


Neurotropic Keratopathy or RGN 352
http://sec.edgar-online.com/regenerx-biopharm...ion10.aspx


Looking for a strategic partnership...

Oct. 20, 2014 - RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
http://regenerx.investorroom.com/2014-10-20-R...eratopathy

"We also look forward to continuing discussions with ophthalmic and pharma companies that have been following our recent progress in this field." stated J.J. Finkelstein, RegeneRx's president and chief executive officer. "As reported in our regulatory filings, we would need to raise additional capital to fully implement this Phase 3 program, or enter a strategic partnership with a company having the resources and capabilities necessary for development of RGN-259," Mr. Finkelstein added."



Hired a part-time CBO to do deals and the CFO quit. Company is low on funds...
Nov. 6, 2014 - RegeneRx Announces Management Changes

http://regenerx.investorroom.com/2014-11-06-R...nt-Changes

"RegeneRx Biopharmaceuticals, Inc. today announced that the Company has retained Alan Klein, MBA, on a part-time basis as Chief Business Officer (CBO) primarily responsible for product licensing, in particular RGN-352, as well as financing initiatives, commercialization modeling, grant applications, and intellectual property development."

"On October 31, 2014, Dane Saglio submitted his resignation as Chief Financial Officer of the Company. Mr. Saglio and the Company have entered into a Consulting Agreement, dated November 1, 2014, pursuant to which Mr. Saglio will perform the duties of principal financial officer of the Company until the filing of the Company's Quarterly Report on Form 10-Q for the third fiscal quarter of 2014. Mr. Saglio will remain as a consultant to the Company after the filing date."